Financial & Business News

When acquisitive Czech billionaire Daniel Kretinsky set his eyes earlier this year on one of Britain's most iconic companies, the Royal Mail, he chose BNP Paribas along with two Wall Street giants to advise him.

FEMSA's Q2 results were mixed, with strong performance from Coca-Cola FEMSA driving the upside and offsetting weaker results in other segments. Weaker growth from Oxxo this quarter isn't a major concern, as calendar effects (the timing of Holy Week) have a lot to do with it and margins continue to improve. Ongoing investments in digital and drugstores may irk some investors, but long-term growth opportunities in core businesses remain promising and worthy of further investment.

LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares ("Ordinary Shares") from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQB Market will be Monday 29 July 2024.

HOUSTON, July 26, 2024 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“VAALCO” or the “Company”) today announced the timing of its second quarter 2024 earnings release and conference call.

The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and COMMAND maintenance trial2 In both trials, SKYRIZI achieved the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including mucosal healing** and histologic endoscopic mucosal healing †, 1 , 2 NORTH CHICAGO, Ill. , July 26, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.3 "Ulcerative colitis is a chronic, unpredictable and sometimes debilitating disease, and people living with the condition need sustained symptom relief," said Edouard Lou

DESCRIPTION OF THE SHARE BUYBACK PROGRAM AUTHORIZED BY THE SHAREHOLDERS' MEETING OF JUNE 5, 2024 Pursuant to Article 241-2 of the General Regulations of the Autorité des Marchés Financiers (AMF), the purpose of this description is to present the objectives and terms of the share buyback program authorized by the Shareholders' meeting of June 5, 2024. Securities concerned: ordinary shares issued by AIR FRANCE – KLM.

LONDON, UK / ACCESSWIRE / July 26, 2024 / The Company announces that on 25 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.

Leonardo and France's Airbus are discussing ways to strengthen collaborations and industrial synergies, the chief executive of the Italian defence group said on Friday.

Flow Traders 2Q 2024 Results Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited 2Q 2024 results.

With Chinese oil demand falling by 8.1%, concerns about consumption rise, putting pressure on WTI prices.